RBC Capital Reiterates Outperform on Alnylam Pharmaceuticals, Maintains $235 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi has reiterated an Outperform rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and maintained a price target of $235.
February 20, 2024 | 3:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital maintains an Outperform rating on Alnylam Pharmaceuticals with a $235 price target.
The reiteration of an Outperform rating and a high price target of $235 by a reputable analyst like Luca Issi from RBC Capital is likely to instill confidence among investors and could lead to a positive short term impact on ALNY's stock price. The analyst's endorsement serves as a strong signal of the company's potential for growth and profitability.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100